Hanmi Pharmaceutical has acquired Aptose Biosciences, Inc., a clinical-stage biotechnology company, for an undisclosed amount. The transaction sees Hanmi Pharmaceutical taking full ownership of Aptose, which focuses on developing first-in-class targeted agents to address unmet clinical needs in multiple hematologic malignancies. This marks a significant corporate acquisition, not a funding round, intended to integrate Aptose's innovative pipeline directly into Hanmi's operations.
Aptose Biosciences is recognized for its precision oncology approach, with a pipeline of small molecule cancer therapeutics. Its lead investigational drug candidates include Luxeptinib and Tuspetinib. Luxeptinib is a potent FLT3/BTK inhibitor being developed for B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphomas (NHL), as well as relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Tuspetinib, a myeloid kinase inhibitor, is in development for the treatment of patients with relapsed or refractory acute myeloid leukemia, targeting multiple kinases operative in myeloid malignancies.
This acquisition is strategically important for Hanmi Pharmaceutical, providing access to a robust clinical-stage oncology pipeline. By acquiring Aptose, Hanmi aims to expand its therapeutic presence in the challenging hematologic cancer space and strengthen its position in precision medicine. The move is expected to leverage Hanmi's existing resources and infrastructure to accelerate the development and potential commercialization of Aptose's promising drug candidates.
Expected synergies from this acquisition include a streamlined development pathway for Luxeptinib and Tuspetinib, potentially bringing these targeted therapies to patients faster. Hanmi Pharmaceutical will integrate Aptose's scientific expertise and innovative drug assets, aiming to create a more comprehensive and impactful oncology portfolio. The combined entity is poised to drive innovation in hematologic oncology, offering new treatment options for patients with limited alternatives.